• Lyell Immunopharma agreed to raise approximately $80 million in gross proceeds through a private placement of common stock.
• The deal covers 7,428,040 shares at $10.77 each, matching the November 3, 2026, closing price.
• Closing is expected on or about November 4, 2026, subject to customary conditions.
• Net proceeds will support ronde-cel trials and regulatory submissions, LYL273 development, and general corporate purposes.
• Financing is expected to extend cash runway into 2028, beyond ronde-cel's planned BLA submission in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040902PRIMZONEFULLFEED9869916) on November 04, 2026, and is solely responsible for the information contained therein.